INTELLECT NEUROSCIENCES, INC. Financial Statements (2025 and earlier)
Company Profile
| Business Address |
550 SYLVAN AVENUE ENGLEWOOD CLIFFS, NJ 07632 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2016 MRQ | 6/30/2015 | 6/30/2014 | 6/30/2013 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 24 | 5 | ||||
| Cash and cash equivalent | 24 | 5 | ||||
| Total current assets: | 24 | 5 | ||||
| Noncurrent Assets | ||||||
| Deposits noncurrent assets | 2 | 2 | 5 | |||
| Total noncurrent assets: | 2 | 2 | 5 | |||
| TOTAL ASSETS: | 26 | 2 | 10 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 2,600 | 2,682 | 2,487 | |||
| Interest and dividends payable | 13,328 | 16,080 | ||||
| Other undisclosed accounts payable and accrued liabilities | (10,729) | (13,398) | 2,487 | |||
| Debt | 2,166 | 1,464 | ||||
| Derivative instruments and hedges, liabilities | 2,683 | 7,209 | 3,833 | |||
| Other undisclosed current liabilities | 13,328 | 16,080 | 6,006 | |||
| Total current liabilities: | 20,777 | 27,436 | 12,327 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 339 | 727 | 1,232 | |||
| Long-term debt, excluding current maturities | 339 | 727 | 1,232 | |||
| Total noncurrent liabilities: | 339 | 727 | 1,232 | |||
| Total liabilities: | 21,116 | 28,163 | 13,558 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (21,090) | (28,161) | (13,548) | |||
| Common stock | 4 | 410 | 209 | |||
| Additional paid in capital | 72,145 | 70,373 | 70,134 | |||
| Accumulated deficit | (93,238) | |||||
| Warrants and rights outstanding | 45 | |||||
| Other undisclosed equity, attributable to parent | (45) | (98,943) | (83,892) | |||
| Total equity: | (21,090) | (28,161) | (13,548) | |||
| TOTAL LIABILITIES AND EQUITY: | 26 | 2 | 10 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2016 TTM | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 1,200 | ||||
| Gross profit: | 1,200 | ||||
| Operating expenses | (2,091) | (1,137) | (4,348) | ||
| Operating loss: | (891) | (1,137) | (4,348) | ||
| Nonoperating income (expense) | 6,596 | (13,914) | (4,708) | ||
| Interest and debt expense | 2,002 | (13,169) | (6,682) | ||
| Income (loss) from continuing operations: | 7,707 | (28,220) | (15,737) | ||
| Income (loss) before gain (loss) on sale of properties: | 7,707 | (28,220) | (15,737) | ||
| Net income (loss): | 7,707 | (28,220) | (15,737) | ||
| Other undisclosed net income (loss) attributable to parent | (2,002) | 13,169 | 6,682 | ||
| Net income (loss) attributable to parent: | 5,705 | (15,052) | (9,056) | ||
| Preferred stock dividends and other adjustments | (700) | ||||
| Net income (loss) available to common stockholders, basic: | 5,705 | (15,052) | (9,756) | ||
| Interest on convertible debt | 1,127 | 290 | |||
| Other undisclosed net income available to common stockholders, diluted | 2,593 | ||||
| Net income (loss) available to common stockholders, diluted: | 6,832 | (15,052) | (6,873) | ||
Comprehensive Income ($ in thousands)
| 3/31/2016 TTM | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Net income (loss): | 7,707 | (28,220) | (15,737) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 7,707 | (28,220) | (15,737) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.